Arcoma Future Growth

Future criteria checks 5/6

Arcoma is forecast to grow earnings and revenue by 20.5% and 7.8% per annum respectively. EPS is expected to grow by 21.4% per annum. Return on equity is forecast to be 22.5% in 3 years.

Key information

20.5%

Earnings growth rate

21.4%

EPS growth rate

Medical Equipment earnings growth	23.5%
Revenue growth rate	7.8%
Future return on equity	22.5%
Analyst coverage	Low
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Apr 26

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Feb 06

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 12

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Dec 17

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Nov 21

Earnings and Revenue Growth Forecasts

OM:ARCOMA - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	213	18	18	23	1
12/31/2025	199	16	13	18	1
12/31/2024	183	14	6	10	1
3/31/2024	172	9	19	21	N/A
12/31/2023	163	3	17	19	N/A
9/30/2023	153	0	-1	3	N/A
6/30/2023	146	0	-2	3	N/A
3/31/2023	138	1	2	8	N/A
12/31/2022	125	2	-4	0	N/A
9/30/2022	105	-6	5	8	N/A
6/30/2022	99	-10	0	2	N/A
3/31/2022	105	-11	-11	-8	N/A
12/31/2021	117	-7	-6	-2	N/A
9/30/2021	126	-6	-10	-7	N/A
6/30/2021	125	-2	-7	-2	N/A
3/31/2021	121	-1	-6	0	N/A
12/31/2020	117	1	-5	7	N/A
9/30/2020	122	8	-14	2	N/A
6/30/2020	130	10	3	20	N/A
3/31/2020	132	10	2	18	N/A
12/31/2019	134	7	0	11	N/A
9/30/2019	133	5	5	11	N/A
6/30/2019	132	2	-3	2	N/A
3/31/2019	129	1	1	4	N/A
12/31/2018	119	-2	-1	0	N/A
9/30/2018	111	-1	-3	-1	N/A
6/30/2018	98	-6	-13	-11	N/A
3/31/2018	94	-10	-11	-8	N/A
12/31/2017	92	-10	N/A	-9	N/A
9/30/2017	98	-9	N/A	0	N/A
6/30/2017	108	-4	N/A	3	N/A
3/31/2017	106	-5	N/A	0	N/A
12/31/2016	102	-12	N/A	-5	N/A
9/30/2016	106	-12	N/A	-12	N/A
6/30/2016	105	-13	N/A	-9	N/A
3/31/2016	104	-15	N/A	-17	N/A
12/31/2015	123	-6	N/A	-5	N/A
9/30/2015	117	-6	N/A	-4	N/A
6/30/2015	119	-5	N/A	-2	N/A
3/31/2015	133	1	N/A	5	N/A
12/31/2014	130	1	N/A	-1	N/A
9/30/2014	134	-7	N/A	-1	N/A
12/31/2013	108	-14	N/A	-12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARCOMA's forecast earnings growth (20.5% per year) is above the savings rate (1%).

Earnings vs Market: ARCOMA's earnings (20.5% per year) are forecast to grow faster than the Swedish market (13.6% per year).

High Growth Earnings: ARCOMA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ARCOMA's revenue (7.8% per year) is forecast to grow faster than the Swedish market (1.7% per year).

High Growth Revenue: ARCOMA's revenue (7.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARCOMA's Return on Equity is forecast to be high in 3 years time (22.5%)

Arcoma Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target decreased to kr16.50

Price target decreased to kr21.00

Analysts update estimates

Price target lowered to kr25.00

Analysts increase EPS estimates to kr0.60

Recent updates

First quarter 2024 earnings released: EPS: kr0.34 (vs kr0.18 loss in 1Q 2023)

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Arcoma AB to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment improves as stock rises 17%

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

New major risk - Market cap size

Is Arcoma (STO:ARCOMA) A Risky Investment?

Third quarter 2023 earnings released: EPS: kr0.15 (vs kr0.11 in 3Q 2022)

We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings released: EPS: kr0.031 (vs kr0.11 in 2Q 2022)

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

First quarter 2023 earnings released: kr0.18 loss per share (vs kr0.093 loss in 1Q 2022)

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Full year 2022 earnings released: EPS: kr0.14 (vs kr0.58 loss in FY 2021)

Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr0.11 (vs kr0.24 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: kr0.11 (vs kr0.079 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Price target decreased to kr16.50

No independent directors

Director recently bought kr119k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr21.00

Third quarter 2021 earnings released: kr0.24 loss per share (vs kr0.082 profit in 3Q 2020)

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Second quarter 2021 earnings released: EPS kr0.079 (vs kr0.18 in 2Q 2020)

First quarter 2021 earnings released: EPS kr0.15 (vs kr0.31 in 1Q 2020)

Is Arcoma (STO:ARCOMA) A Risky Investment?

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS kr0.12 (vs kr0.52 in FY 2019)

Arcoma AB, Annual General Meeting, May 25, 2021

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Insider recently sold kr390k worth of stock

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Investor sentiment improved over the past week

New 90-day high: kr21.90

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Arcoma AB Launches Omnera 500A

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Third quarter 2020 earnings released: EPS kr0.082

Analysts update estimates

Price target lowered to kr25.00

New 90-day low: kr17.00

New 90-day low: kr17.50

Analysts increase EPS estimates to kr0.60

Earnings released

New 90-day low - kr17.70

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies